Compare Cassava Sciences Inc (FLNA) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Global Payments Inc — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Global Payments Inc trades at $81.65 (market cap $21.46B). The key difference: Global Payments Inc is far larger — about 544.7× Cassava Sciences Inc's market cap, and Global Payments Inc pays a 1.23% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Global Payments Inc for 50 Days on average.
| FLNA | GPN | |
|---|---|---|
Market Cap | $39.40M | $21.46B |
Volume | 759,018 | 1,482,600 |
Sector | Health | Financials |
52-Week High | $4.64 | $94.83 |
52-Week Low | $0.68 | $62.47 |
Typical Hold Time | 37 Days | 50 Days |
Enterprise Value | -$43.28M | $39.60B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Global Payments (GPN) trades at $82.20, up 1.38% on the day, with a neutral technical signal and bullish moving averages. The stock has beaten EPS estimates for three consecutive quarters, though Q3 2026 results are pending. Revenue declined to $7.71B in 2025, but net income margin improved to 18.16%. Analyst consensus is bullish with a $102.75 price target, representing significant upside. Recent news highlights growth initiatives like the Genius platform and Worldpay integration.
GPN offers potential upside based on strong analyst sentiment and strategic initiatives, but faces risks from rising costs, high debt levels, and competitive pressures. The negative net income margin projection for 2026 underscores execution challenges. Investors should weigh the company's digital payment growth against macroeconomic and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
